Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver

Colorectal Cancer Clinical Trial

Official title:

A Phase I/II, Open-label Study to Evaluate the Safety and Anti-tumor Effects of NV1020 Administered Repeatedly Via Hepatic Artery Infusion Prior to Second-line Chemotherapy, in Patients With Colorectal Adenocarcinoma Metastatic to the Liver

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00149396
• Other study ID #: CT1030
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: September 6, 2005
• Last updated: March 21, 2018
• Start date: July 2004
• Est. completion date: December 2008

Study information

• Verified date: March 2018
• Source: MediGene
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is an open-label study. It has two stages. Stage 1 is a dose escalation phase of the study to determine and evaluate the safety and tolerability of repeated treatments with a genetically engineered herpes simplex virus NV1020 administered locoregionally to the liver.

Stage 2 is to evaluate the dose found in Stage 1 to be "optimally tolerated". Stage 2 is to assess the efficacy of the optimally tolerated dose of NV1020 by itself and in combination with second-line chemotherapy.

Assignment to Stage 1 or Stage 2 of the study is determined by when the patient enters the study.

Description:

This study is designed to evaluate the effects of repeated treatments with NV1020, prior to second-line chemotherapy, and to determine an appropriate dose level of NV1020 in a multiple dose regimen for later Phase II studies.

Sequential, open-label cohort dose escalation of NV1020 (stage 1) followed by an expansion of one selected dose cohort (stage 2).

Study results will be reviewed periodically by an independent DSMB who will approve each cohort dose escalation.

During the dose escalation stage, 3 cohorts of patients (3 in each) will be treated with 4 fixed doses of NV1020, with the dose level increasing for successive cohorts. A patient will be observed for a minimum of 7 days after the first NV1020 infusion before the next patient in the same cohort is given NV1020. The first patient in the next higher dose cohort will receive NV1020 no earlier than 14 days after the last patient in the prior cohort has finished NV1020 infusions. One additional cohort (half log higher increment) may be approved by the DSMB, if considered necessary to define MTD. Dose-limiting toxicity will be determined using NCI CTC criteria and a suitable dose level for later evaluation will be selected.

In the second stage of the study, the dose cohort considered to show the best therapeutic index will be expanded by the addition of 18 further patients. For all patients in this study, investigational treatment with NV1020 will be followed by a minimum of two cycles of second-line therapy using anti-neoplastic drugs approved by the FDA for colorectal cancer and selected by the investigator.

All patients will be followed up periodically until death. Permission for autopsy will be sought.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: December 2008
• Est. primary completion date: October 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Ability to understand and willingness to sign a written informed consent (includes willingness to avoid physical intimacy during and for 2 weeks post NV1020 treatment)

2. 18 years or more of age

3. Colorectal adenocarcinoma histologically confirmed within one year prior to enrollment in the study

4. Liver dominant metastases (CT-measurable lesions with less than 50% total liver involvement), histologically confirmed

5. Failed conventional chemotherapy for metastatic disease (e.g. tumors no longer responding to 5-FU/leucovorin in combination with irinotecan or oxaliplatin with or without one monoclonal antibody)

6. Candidate for additional chemotherapy (and/or experimental anti-cancer therapy, if this is the only remaining treatment option)

7. Karnofsky Performance Status 70% or greater

8. Life expectancy greater than or equal to 4 months, based on the investigator's opinion

9. Seropositive for herpes simplex virus-1 (HSV-1)

10. Fecund females: negative for pregnancy test (urine or serum)

11. Effective double-barrier contraception for a minimum of 2 months following final infusion of NV1020

Exclusion Criteria:

1. Dominant extrahepatic disease, including cerebral metastases, significant malignant ascites or other extrahepatic metastases that are symptomatic, in critical locations or otherwise likely to confound NV1020 evaluations, in the opinion of the investigator

2. Seronegative for HSV-1

3. Significant active/unstable non-malignant disease or laboratory test (hematology and chemistry) results that meet any of the following:

• White blood cell count (WBC) less than or equal to 3 x 10e3/mm3

• Absolute neutrophil count (ANC) less than or equal to 1.5 x 10e3/mm3

• Platelets less than or equal to 100,000/mm3

• Hemoglobin (Hgb) less than or equal to 9.0 g/dL

• Prothrombin time/partial thromboplastin time (PT/PTT) > upper limit of normal (ULN)

• Serum creatinine > 2.0 mg/dL

• Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 times ULN or total bilirubin > 1.5 times ULN

• Alkaline phosphatase > 2.5 times ULN

4. Chemotherapy < 4 weeks prior to the first NV1020 infusion (mitomycin or nitrosurea < 6 weeks)

5. Immunotherapy < 6 weeks prior to the first NV1020 infusion

6. Radiotherapy (external or internal) to the liver

7. Major surgery (excluding pump placement and cholecystectomy) = 2 weeks prior to the first NV1020 infusion but the subject must be clinically stable. Pump placement and cholecystectomy = 1 week prior to the first NV1020 infusion but the subject must be clinically stable

8. Female who is pregnant or nursing

9. Patients wishing to conceive within 2 months after the last infusion of NV1020

10. Any investigational agent administered less than or equal to 4 weeks prior to NV1020 infusion

11. Acute HSV infection requiring systemic antiviral therapy or history of serious HSV infection (e.g., ocular, encephalitic, etc.)

12. Active viral hepatitis (evidence for infection with hepatitis A, B or C viruses)

13. Known infection with HIV

14. Known hypersensitivity to any component of the NV1020 formulation

15. History of, or current, bleeding or coagulation disorder

16. History of significant hepatic fibrosis, cirrhosis, or hemachromatosis

17. History of malignancy other than colorectal cancer, within 5 years prior to start of study participation, with the exception of in situ cervical or skin carcinoma

18. Active severe infection and any other concurrent disease or medical conditions that are likely to interfere with the study, as judged by the investigator

19. Systemic corticosteroid administration < 4 weeks prior to starting NV1020 treatment

20. Prior treatment with NV1020 or other putative oncolytic viruses

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms
• Liver Neoplasms
• Neoplasms

Intervention

Drug:
• NV1020
NV1020 dose levels: 3x10^6, 1x10^7, 3x10^7, and 1x10^8 plaque forming units, administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks

Locations

Country	Name	City	State
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	Mary Crowley Medical Research Center	Dallas	Texas
United States	University of Vanderbilt	Nashville	Tennessee
United States	University of Pittsburgh Cancer Center	Pittsburgh	Pennsylvania
United States	University of California, San Diego	San Diego	California

Sponsors (1)

Lead Sponsor	Collaborator
MediGene

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Adverse Events and Dose Limiting Adverse Events	Incidence of adverse events for all patients (N=32); Overall incidence =20%; Adverse events listed by Medical Dictionary for Regulatory Activities (MedDRA) Preferred Term	From start of treatment through 12 months after completion of treatment
Primary	NV1020 Pharmacokinetics - Presence of NV1020 in Body Fluids/Skin	Number of patients with NV1020 detected in saliva, skin, and/or mucosal surfaces; Analysis by polymerase chain reaction (PCR)	Daily for 2 weeks after the first and last NV1020 infusions
Primary	Clinical Laboratory Safety - Hematology	Number of patients with clinically significant hematology laboratory abnormalities by NV1020 dose cohort (Post baseline)	Screening; after each NV1020 infusion; +7h, +24h, and +72h after NV1020 infusion; each chemotherapy visit; +3d, +7d, +14d after each chemo visit; 1 week after end of treatment
Primary	Clinical Laboratory Safety - Chemistry	Number of patients with post-baseline clinically significant laboratory chemistry abnormalities by NV1020 dose cohort	Screening; after each NV1020 infusion; +7h, +24h, and +72h after NV1020 infusion; each chemotherapy visit; +3d, +7d, +14d after each chemo visit; 1 week after end of treatment
Primary	Clinical Laboratory Safety - Coagulation	Number of patients with post-baseline clinically significant laboratory coagulation abnormalities by NV1020 dose cohort	Screening; after each NV1020 infusion; +7h, +24h, and +72h after NV1020 infusion; each chemotherapy visit; +3d, +7d, +14d after each chemo visit; 1 week after end of treatment
Secondary	Mean Change From Baseline in Serum Carcinoembryonic Antigen (CEA) After Administration of NV1020 and 2 Cycles of Chemotherapy		Screening (baseline), Chemo visit 1, Chemo visit 2, Follow-up Visit 1 (1 week after end of treatment), Follow-up Visit 2 (+6M), Follow-up Visit 3 (+9M), Follow-up Visit 4 (+12M)
Secondary	Liver Tumor Response After Administration of NV1020 Followed by Chemotherapy, Determined by Radiological (Computed Tomography [CT] Scan) Assessment	Maximum percentage changes in tumor diameter after administration of NV1020 followed by chemotherapy as measured by CT scan and Modified Response Evaluation Criteria in Solid Tumors (RECIST) assessment	Screening (baseline), Chemo visit 1, Follow-up visits 1 (1 week post end of treatment), 2 (+6M), 3 (+9M), 4 (+12M)
Secondary	Pharmacodynamic Effects of NV1020: NV1020 Neutralizing Antibody Titer Assay	Mean change from baseline in NV1020 neutralizing antibody titer by dose cohort	Screening, Chemo Visit 1, Follow-up Visits 1 (1 week post end of treatment), 2 (+6M), 3 (+9M), 4 (+12M)
Secondary	Time to Disease Progression; Survival Time	Progression assessed from CT and PET measurements and is determined as an increase of greater than or equal to 25% in the sum of the products of perpendicular diameters of all tumors, or the appearance of any new lesion.	Progression: Chemo visit 1, FU1 (1 week post treatment), FU2 (+6M), FU3 (+9M), FU4 (+12M); Survival: death of patient
Secondary	Pharmacodynamic Effects of NV1020: Serum Cytokines (INF Gamma)	Median change from baseline of Interferon (INF) gamma 8 hours post NV1020 infusion (Visits 1, 3, 5, 7)	Baseline, after each NV1020 infusion (Visit 1, Visit 3, Visit 5, Visit 7)
Secondary	Pharmacodynamic Effects of NV1020: Serum Cytokines (IL-6)	Median change from baseline of Interleukin-6 (IL-6) 8 hours post NV1020 infusion (Visits 1, 3, 5, 7)	Baseline, after each NV1020 infusion (Visit 1, Visit 3, Visit 5, Visit 7)
Secondary	Pharmacodynamic Effects of NV1020: Serum Cytokines (TNF-alpha)	Median change from baseline of tumor necrosis factor (TNF-alpha) 8 hours post NV1020 infusion (Visits 1, 3, 5, 7)	Baseline, after each NV1020 infusion (Visit 1, Visit 3, Visit 5, Visit 7)